Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Pharmalot By Ed Silverman July 24, 2018 Reprints What’s included? Hello, everyone, and how are you today? We are doing just fine, thank you, as a comfortable breeze and hazy skies make the Pharmalot campus a rather comfortable work space this morning. Moreover, we fired up the coffee kettle on our way to brewing a steady supply of cups of stimulation. Our initial flavor this morning is blueberry, a summer special. Please feel free to join us. Remember, no prescription is required. So no rebates factor in to your cost. What more could you ask? Meanwhile, here are some tidbits. Hope you have a wonderful day and, of course, do keep in touch …Just 27 percent of Americans have heard or read about the Trump administration blueprint for reducing drug costs, a Politico poll finds. And 57 percent believe the plan will not make a difference, while 13 percent believe they or their family will pay more. Meanwhile, 22 percent believe the plan will lower the price they or their family pay for prescription drugs. And many more Americans believe drug makers — not pharmacy benefit managers — are responsible for high prices. Republicans are more likely than Democrats to believe the Trump plan will lower drug prices. What is it? [email protected] GET STARTED @Pharmalot About the Author Reprints Alex Hogan/STAT Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED Pharmalittle: Most Americans think Trump drug plan will not matter; Ohio readies lawsuit against PBMs Ed Silverman Log In | Learn More Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Tags Donald Trumpdrug pricinglegalpharmaceuticalspharmalittleSTAT+ STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.